Figure 2From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patientsComorbidity pattern of patients with or without the metabolic syndrome (Total n = 14,200). PAD – peripheral arterial disease; PTCA – Percutaneous transluminal coronary angiography; MI – Myocardial infarction; TIA – Transient ischemic attack; LVH – Left ventricular hypertrophy, CHD – Coronary heart disease; Met (+) – Patients with the metabolic syndrome (doctors diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: Chi2-testBack to article page